Selective Sparing of Human Tregs by Pharmacologic Inhibitors of the Phosphatidylinositol 3‐Kinase and MEK Pathways

Phosphatidylinositol 3‐kinase (PI3K) and mitogen‐activated protein kinase/extracellular signal‐regulated (MEK) signaling are central to the survival and proliferation of many cell types. Multiple lines of investigation in murine models have shown that control of the PI3K pathway is particularly important for regulatory T cell (Treg) stability and function. PI3K and MEK inhibitors are being introduced into the clinic, and we hypothesized that pharmacologic inhibition of PI3K, and possibly MEK, in mixed cultures of human mononuclear cells would preferentially affect CD4+ and CD8+ lymphocytes compared with Tregs. We tested this hypothesis using four readouts: proliferation, activation, functional suppression, and signaling. Results showed that Tregs were less susceptible to inhibition by both δ and α isoform–specific PI3K inhibitors and by an MEK inhibitor compared with their conventional CD4+ and CD8+ counterparts. These studies suggest less functional reliance on PI3K and MEK signaling in Tregs compared with conventional CD4+ and CD8+ lymphocytes. Therefore, the PI3K and MEK pathways are attractive pharmacologic targets for transplantation and treatment of autoimmunity.

[1]  E. Guinan,et al.  Ex Vivo Costimulatory Blockade to Generate Regulatory T Cells From Patients Awaiting Kidney Transplantation , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  L. Platanias,et al.  Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase , 2015, Oncotarget.

[3]  Jie Shen,et al.  Combination treatment with perifosine and MEK-162 demonstrates synergism against lung cancer cells in vitro and in vivo , 2015, Tumor Biology.

[4]  E. Shevach,et al.  Foxp3‐mediated inhibition of Akt inhibits Glut1 (glucose transporter 1) expression in human T regulatory cells , 2015, Journal of leukocyte biology.

[5]  L. Turka,et al.  T-cell energy metabolism as a controller of cell fate in transplantation , 2015, Current opinion in organ transplantation.

[6]  H. Chi,et al.  Regulatory T cells require the phosphatase PTEN to restrain type 1 and follicular helper T-cell responses , 2015, Nature Immunology.

[7]  E. Kohn,et al.  The MAPK pathway across different malignancies: A new perspective , 2014, Cancer.

[8]  Xuyu Zhou,et al.  Constitutive Activation of MEK1 Promotes Treg Cell Instability in Vivo* , 2014, The Journal of Biological Chemistry.

[9]  J. Berzofsky,et al.  Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway , 2014, Cancer Immunology Research.

[10]  B. Rueda,et al.  Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer. , 2014, Gynecologic oncology.

[11]  J. Cebon,et al.  MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells , 2014, Cancer Immunology Research.

[12]  T. Rao,et al.  PI3Kγ kinase activity is required for optimal T-cell activation and differentiation , 2013, European journal of immunology.

[13]  Qingyang Wang,et al.  Cyclic AMP suppresses TGF-β-mediated adaptive Tregs differentiation through inhibiting the activation of ERK and JNK. , 2013, Cellular immunology.

[14]  C. Elson,et al.  ERK differentially regulates Th17‐ and Treg‐cell development and contributes to the pathogenesis of colitis , 2013, European journal of immunology.

[15]  K. Komanduri,et al.  MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner. , 2013, Blood.

[16]  James B. Mitchell,et al.  PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer , 2013, Clinical Cancer Research.

[17]  A. Tapia-Abellán,et al.  Role of MAP Kinases and PI3K‐Akt on the cytokine inflammatory profile of peritoneal macrophages from the ascites of cirrhotic patients , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[18]  K. Okkenhaug Signaling by the phosphoinositide 3-kinase family in immune cells. , 2013, Annual review of immunology.

[19]  K. Okkenhaug Rules of engagement: distinct functions for the four class I PI3K catalytic isoforms in immunity , 2013, Annals of the New York Academy of Sciences.

[20]  M. Murakami,et al.  JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. , 2012, Cancer cell.

[21]  R. Schwartz,et al.  Endothelial PI3K-C2α, a class II PI3K, has an essential role in angiogenesis and vascular barrier function , 2012, Nature Medicine.

[22]  J. Pouysségur,et al.  Polar Opposites: Erk Direction of CD4 T Cell Subsets , 2012, The Journal of Immunology.

[23]  M. Levings,et al.  The Role of the PI3K Signaling Pathway in CD4+ T Cell Differentiation and Function , 2012, Front. Immun..

[24]  Dalya R. Soond,et al.  Does the PI3K pathway promote or antagonize regulatory T cell development and function? , 2012, Front. Immun..

[25]  Graham M Lord,et al.  A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. , 2012, Blood.

[26]  Jordi Rodon,et al.  Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  K. Torgersen,et al.  T Cell-Signaling Network Analysis Reveals Distinct Differences between CD28 and CD2 Costimulation Responses in Various Subsets and in the MAPK Pathway between Resting and Activated Regulatory T Cells , 2011, The Journal of Immunology.

[28]  A. Putnam,et al.  Rapid assessment of in vitro expanded human regulatory T cell function. , 2011, Journal of immunological methods.

[29]  P. Zapater,et al.  Peritoneal macrophage priming in cirrhosis is related to ERK phosphorylation and IL‐6 secretion , 2011, European journal of clinical investigation.

[30]  C. Stuelten,et al.  Positive and negative transcriptional regulation of the Foxp3 gene is mediated by access and binding of the Smad3 protein to enhancer I. , 2010, Immunity.

[31]  J. Haugh,et al.  Systematic Quantification of Negative Feedback Mechanisms in the Extracellular Signal-regulated Kinase (ERK) Signaling Network* , 2010, The Journal of Biological Chemistry.

[32]  S. Zheng,et al.  Role of SMAD and Non-SMAD Signals in the Development of Th17 and Regulatory T Cells , 2010, The Journal of Immunology.

[33]  Dalya R. Soond,et al.  PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. , 2010, Blood.

[34]  P. Bruneval,et al.  Regulatory T Cells in Kidney Allograft Infiltrates Correlate With Initial Inflammation and Graft Function , 2010, Transplantation.

[35]  M. Turner,et al.  Thymic development beyond β-selection requires phosphatidylinositol 3-kinase activation by CXCR4 , 2010, The Journal of experimental medicine.

[36]  J. Haugh,et al.  PI3K-dependent cross-talk interactions converge with Ras as quantifiable inputs integrated by Erk , 2009, Molecular systems biology.

[37]  David K. Finlay,et al.  T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR , 2008, Proceedings of the National Academy of Sciences.

[38]  R. V. van Lier,et al.  Differential Regulation of Human IL-7 Receptor α Expression by IL-7 and TCR Signaling1 , 2008, The Journal of Immunology.

[39]  Karin Jirström,et al.  From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 28, 2013. For personal use only. , 2006 .

[40]  K. Okkenhaug,et al.  Inactivation of PI3Kgamma and PI3Kdelta distorts T-cell development and causes multiple organ inflammation. , 2007, Blood.

[41]  R. Lechler,et al.  The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. , 2007, International immunology.

[42]  A. Rudensky,et al.  Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice , 2007, Nature Immunology.

[43]  Hailing Cheng,et al.  The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation , 2006, Proceedings of the National Academy of Sciences.

[44]  T. Gingeras,et al.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.

[45]  W. Swat,et al.  Essential role of PI3Kdelta and PI3Kgamma in thymocyte survival. , 2006, Blood.

[46]  E. Vigorito,et al.  Cutting Edge: T Cell Development Requires the Combined Activities of the p110γ and p110δ Catalytic Isoforms of Phosphatidylinositol 3-Kinase1 , 2005, The Journal of Immunology.

[47]  Wan-Wan Lin,et al.  PKA-dependent activation of PKC, p38 MAPK and IKK in macrophage: implication in the induction of inducible nitric oxide synthase and interleukin-6 by dibutyryl cAMP. , 2004, Cellular signalling.

[48]  S. Ziegler,et al.  Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. , 2003, The Journal of clinical investigation.

[49]  O. Dittrich‐Breiholz,et al.  Multiple control of interleukin‐8 gene expression , 2002, Journal of leukocyte biology.

[50]  Magnus Bosse,et al.  Regulation of Raf-Akt Cross-talk , 2002, The Journal of Biological Chemistry.

[51]  A. Filipovich,et al.  Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome , 2002, Journal of medical genetics.

[52]  K. Okkenhaug,et al.  Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice , 2002, Science.

[53]  L. Cantley,et al.  Phosphoinositide 3-kinase in immunological systems. , 2002, Seminars in immunology.

[54]  D. Thuerauf,et al.  p38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. , 2000, The Journal of biological chemistry.

[55]  W L Stanford,et al.  Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. , 2000, Science.

[56]  Silvano Sozzani,et al.  Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation , 2000 .

[57]  E. Johns,et al.  Modulation of interleukin-6 by beta2-adrenoceptor in endotoxin-stimulated renal macrophage cells. , 1999, Kidney international.

[58]  H. Gudmundsdottir,et al.  Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. , 1997, The Journal of clinical investigation.

[59]  V. Godfrey,et al.  X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. , 1991, The American journal of pathology.

[60]  R. Gershon A Disquisition on Suppressor T Cells , 1975, Transplantation reviews.

[61]  K. Okkenhaug,et al.  This information is current as Signaling in CD 8 T Cells S 6 Phosphorylation to Control Metabolic Converge at the Level of Ribosomal Protein Mammalian Target of Rapamycin Pathways MAPK , Phosphatidylinositol 3-Kinase , and , 2009 .

[62]  P. Finan,et al.  PI(3)Kgamma has an important context-dependent role in neutrophil chemokinesis. , 2007, Nature cell biology.

[63]  C. Rommel,et al.  Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. , 2005, Nature medicine.

[64]  Ray H. Baughman,et al.  Supporting Online Material , 2003 .

[65]  C. Garlanda,et al.  Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. , 2000, Science.